outperform price
report morn highlight
rais ep guidanc reflect growth
guid ou humira sale vs
that declin due usd
strength past year
reflect
oper declin
project
clear
compani comfort origin biosimilar
eros project see softer y/i
declin lap introduct
biosimilar
sometim
hcv market share grew us ou impact
de-wareh
orilissa run rate grow
comfort guidanc
 l-dopa/carbidopa parkinson
egfr-target gbm
myelofibrosi decis advanc earli
random studi well antagonist
jak/btk inhibitor combo
tnf/steroid
tabl key product perform updat
guidanc revis pt reflect
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
steeper eros humira due fx addit risa
royalti cf statement
track rel beat/miss
commentari around product serial around quarter includ
serial guidanc updat
addit commentari key programs/pipelin
deriv pt use dcf discount rate termin
growth rate discount rate standard rate appli across derisk biopharma compani
reflect believ appropri return sharehold termin growth rate reflect
durabl natur compani biolog franchis
clearli humira domin product framework biosimilar adopt chang humira
method use patent fall multipl biosimilar launch simultan creat pent-up
precipit impact sale share could suffer
articl articl
time dissemin april
analyst josh schimmer shenston huang ravi mehrotra regina grebla maneka mirchandaney primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
